Rafferty Asset Management
SPRY icon

Rafferty Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Rafferty Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$509K Sell
63,574
-54,061
-46% -$465K ﹤0.01% 895
2026
Q1 		$945K Buy
117,635
+2,071
+2% +$19.8K ﹤0.01% 785
2025
Q4 		$1.35M Sell
115,564
-6,846
-6% -$66.6K ﹤0.01% 744
2025
Q3 		$1.23M Buy
122,410
+41,564
+51% +$597K ﹤0.01% 747
2025
Q2 		$1.41M Buy
80,846
+5,524
+7% +$79.7K ﹤0.01% 692
2025
Q1 		$948K Sell
75,322
-65,050
-46% -$783K ﹤0.01% 753
2024
Q4 		$1.48M Buy
140,372
+59,097
+73% +$828K 0.01% 716
2024
Q3 		$1.18M Sell
81,275
-4,042
-5% -$48.1K ﹤0.01% 769
2024
Q2 		$726K Sell
85,317
-26,242
-24% -$233K ﹤0.01% 873
2024
Q1 		$1.14M Buy
+111,559
New +$832K ﹤0.01% 810

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Rafferty Asset Management's SPRY Position: Q2 2026 in Review

Rafferty Asset Management reduced its ARS Pharmaceuticals (SPRY) stake by 46% in Q2 2026, selling an estimated $465K and leaving 63,574 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #895.

Rafferty Asset Management first reported a position in SPRY in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.48M in Q4 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Rafferty Asset Management held 63,574 shares of ARS Pharmaceuticals worth $509K as of Q2 2026.
  • Rafferty Asset Management sold 54,061 ARS Pharmaceuticals shares in Q2 2026, an estimated $465K.
  • ARS Pharmaceuticals made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #895 holding.
  • Rafferty Asset Management first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Rafferty Asset Management's ARS Pharmaceuticals position peaked at $1.48M in Q4 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.